The past 15 years for Geistlich Pharma have been characterized by expansion. Paul Note as CEO for many years, Rolf Jeger as CFO / later Director GRC and Terance Hart as CSO / later Director Research played a major role in this development. Their important achievements included the expansion of the global structure with the establishment of numerous affiliates for the distribution of biomaterials, the establishment of strong global brands and the outstanding positioning of Geistlich as a supplier of regenerative products with innovative concepts for marketing and training. Production was successively expanded, as were all the supporting processes. During this time, the Geistlich Pharma team grew from 140 to over 700 employees.
Paul Note already got to know Geistlich in the period from 1986 to 1987. At that time, he worked as a consultant at Hayek Engineering and was hired to do a more in-depth analysis of Ed. Geistlich Sons. He was then brought into the company as CEO by Dr. Peter Geistlich in 2006. Since then, he has continued to run Geistlich Pharma in the spirit of the pioneer. With his great gift for establishing human contacts in an engaging manner, he carefully cultivated the network with the scientific community in order to always achieve the best results for patients. He always mastered challenging situations coupled with a confidence-building optimism and a great commitment to the well-being of the workforce. For more than 10 years, Paul Note was active as a trustee of the Osteology Foundation. As part of the Foundation Board, he has facilitated its sustainable evolution into a global provider of continuing education & research funding in oral tissue regeneration. With the end of his term on the Foundation Board, he will continue to serve the Foundation as an "Osteology Honorary Board Member".
Reacting prudently in difficult situations was one of Rolf Jeger's great strengths. For financial planning, the termination of the minimum euro exchange rate in 2015 and the COVID-19 crisis in particular represented a major challenge. Terance Hart, with his enthusiasm for Geistlich Biomaterials, expanded Research & Development and contributed significantly to a deeper understanding of what makes our Geistlich products unique in their biological properties and clinical performance.
Paul Note, Rolf Jeger and Terance Hart have given the company a new appearance and strengthened it for the future. Now, after 15, 12 and 11 years, they are retiring in mid-2021. And after all their tireless efforts, this retirement is indeed well deserved. The Board of Directors and the entire staff wish the three gentlemen all the best and thank them for their always loyal and goal-oriented cooperation and their humanly obliging manner. We wish them much happiness and joy for all future projects and activities as well as good health for them and their families.
We wish the new management under the leadership of Ralf Halbach much success and joy in the further development of Geistlich Pharma AG.
The Board of Directors of Geistlich Pharma AG